Pamorelin (Triptorelin)

Pamorelin is a GnRH‑agonist that modulates the hypothalamic‑pituitary‑gonadal axis in several hormone‑dependent disease states.

• Prostate cancer: provides androgen suppression to slow tumor progression.
• Endometriosis: induces a hypo‑estrogenic state to reduce pelvic pain and lesion growth.
• Assisted reproductive technology (ART) protocols: prevents premature luteinizing hormone surge during controlled ovarian stimulation.
• Uterine fibroids: creates a low‑estrogen environment that can shrink fibroid size and lessen bleeding.
• Precocious precocious puberty: delays further sexual development by suppressing gonadotropin release.

• Triptorelin is a synthetic decapeptide that binds with high affinity to GnRH receptors in the anterior pituitary gland. Continuous stimulation leads to receptor desensitisation and down‑regulation, markedly reducing the secretion of luteinising hormone (LH) and follicle‑stimulating hormone (FSF). The consequent drop in circulating sex steroids (testosterone and estradiol) underlies its therapeutic effects in hormone‑dependent conditions.

Side effects vary with treatment duration and patient characteristics.

Common Side Effects

• Hot flashes
• Headache
• Injection site pain or erythema
• Fatigue
• Mood changes
• Decreased libido

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis)
• Cardiovascular events such as myocardial infarction
• Bone density loss leading to osteoporosis
• Liver function abnormalities
• Pituitary apoplexy (very rare)
• Severe depression or suicidal ideation

When prescribing Pamorelin, clinicians should consider several safety aspects.

• Cardiovascular assessment: evaluate history of heart disease before initiating therapy.
• Bone health monitoring: periodic bone mineral density scans are advised for long‑term use.
• Hormone‑dependent tumor surveillance: continue regular oncologic assessments.
• Pregnancy and lactation: avoid use in women who are pregnant, planning pregnancy or breastfeeding.
• Drug interactions: review concomitant medications for potential CYP‑related effects.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Triptorelin may interact with several drug classes; awareness helps prevent reduced efficacy or heightened toxicity.

Major Interactions (Avoid)

• Combined androgen‑deprivation therapy (ADT) with other GnRH agonists or antagonists – risk of excessive hormone suppression.\nModerate Interactions (Monitor Closely):
• CYP3A4 inhibitors (e.g., ketoconazole) – may alter hormone levels.
• Anticoagulants (warfarin) – increased bleeding risk at injection sites.\n- Steroid ​​​ ​  ​  ​ ​ ​ ​ ​ ​ ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​ ​  ​​ ​ ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​  ​ ​​  ​  ​ ​  ​ ​  ​ ​​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​
• Hormone replacement therapy (estrogen or testosterone): may blunt the intended suppressive effect.
• Antidepressants (SSRIs): monitor mood changes as triptorelin can affect emotional state.
• Bisphosphonates: consider bone health strategy when long‑term therapy is planned.